Gornitzky represented the underwriters, led by Cantor Fitzgerald and Nomura Securities, in RedHill Biopharma’s USD 22.5 million underwritten public offering of American Depositary Shares (ADSs) on the NASDAQ Capital Market. RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer, is dually traded on the NASDAQ and the Tel Aviv Stock Exchange (NASDAQ: RDHL, TASE: RDHL).
Cantor Fitzgerald and Nomura Securities acted as joint book-running managers for the offering. SMBC Nikko Securities acted as lead manager and H.C. Wainwright and Roth Capital acted as co-managers for the offering.
The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Nir Knoll (Associate).
